LAG3 Antikörper (N-Term)
Kurzübersicht für LAG3 Antikörper (N-Term) (ABIN1169105)
Target
Alle LAG3 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Bindungsspezifität
- N-Term
-
Spezifität
- Recognizes human LAG-3.
-
Kreuzreaktivität
- Human
-
Reinheit
- >95 % (SDS-PAGE)
-
Endotoxin-Niveau
- <0.001EU/μg purified protein or <1EU/mg purified protein (LAL test, Lonza).
-
Immunogen
- Synthetic peptide corresponding to 30 aa in the N-terminus of human LAG-3.
-
Isotyp
- IgG1
-
-
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- Lot specific
-
Buffer
- In PBS containing 0.02 % sodium azide.
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- 4 °C,-20 °C
-
Informationen zur Lagerung
-
Short Term Storage: +4°C
Long Term Storage: -20°C
Stable for at least 1 year after receipt when stored at -20°C. -
Haltbarkeit
- 12 months
-
-
-
: "A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors." in: Cancer letters, Vol. 235, Issue 1, pp. 147-53, (2006) (PubMed).
: "The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells." in: Immunology, Vol. 115, Issue 2, pp. 170-8, (2005) (PubMed).
: "Immunological mechanisms elicited at the tumour site by lymphocyte activation gene-3 (LAG-3) versus IL-12: sharing a common Th1 anti-tumour immune pathway." in: The Journal of pathology, Vol. 205, Issue 1, pp. 82-91, (2004) (PubMed).
: "T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts." in: European journal of cancer (Oxford, England : 1990), Vol. 37, Issue 13, pp. 1709-18, (2001) (PubMed).
: "CD3/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 161, Issue 8, pp. 4058-65, (1998) (PubMed).
: "Characterization of the major histocompatibility complex class II binding site on LAG-3 protein." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 94, Issue 11, pp. 5744-9, (1997) (PubMed).
: "Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand." in: Immunogenetics, Vol. 39, Issue 3, pp. 213-7, (1994) (PubMed).
: "Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens." in: The Journal of experimental medicine, Vol. 176, Issue 2, pp. 327-37, (1992) (PubMed).
-
-
- LAG3 (Lymphocyte-Activation Gene 3 (LAG3))
-
Andere Bezeichnung
- LAG-3
-
Hintergrund
- Lymphocyte activation gene 3 (LAG-3, CD223) plays an important role in negatively regulating T cell proliferation, function and homeostasis. It is required for maximal natural and induced regulatory T cell (Treg) function. LAG-3 is closely related to the T cell co-receptor CD4 and binds to MHC class II molecules but with a significantly higher affinity than CD4.
-
UniProt
- P18627
-
Pathways
- Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints
Target
-